

## FOI Request re Number of Patients Treated

Please detail the number of Oncology patients treated<sup>1</sup> (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months **January 2018 to December 2018** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated (regardless of Tumour Type)	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	72	1	16		52	
Nivolumab (Opdivo)	51	2	12		5	17
Ipilimumab (Yervoy)	2	1	1			
Nivolumab & Ipilimumab						
Dabrafenib (Tafinlar)	51	8	19		4	17
Cabozantinib (Cabometyx)	5					4
Sunitinib (Sutent)	0					
Pazopanib (Votrient)	10					10
Axitinib (Inlyta)	5					5
Atezolizumab (Tecentriq)	11				11	
Sorafenib (Nexavar)	7					1
Tivozanib (Fotivda)	0					
Cetuximab (Erbix)	11	5				
Everolimus (Afinitor)	21					6
Vemurafenib (Zelboraf)	0					
Total Number Treated (all treatments)	246	17	48		72	60

### Notes

1. Reporting system does not allow for multiple regimens therefore cannot check for Nivolumab & Ipilimumab.
2. Report does not indicate whether drugs are for Adjuvant ant or Metastatic Melanoma however all diagnosis where registered as 'Primary' for these patients and therefore are assumed to be non-metastatic.

<sup>1</sup> Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).